scholarly journals Identification TRIM46 as a Potential Biomarker and Therapeutic Target for Clear Cell Renal Cell Carcinoma Through Comprehensive Bioinformatics Analyses

2021 ◽  
Vol 8 ◽  
Author(s):  
Xiang-bin Ren ◽  
Jing Zhao ◽  
Xue-feng Liang ◽  
Xu-dong Guo ◽  
Shao-bo Jiang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Immunity ◽  
Renal Cell ◽  
Clear Cell ◽  
Strong Positive Correlation ◽  
Cell Renal Cell Carcinoma ◽  
Bioinformatics Analyses ◽  
Potential Biomarker ◽  
Tripartite Motif

Background: Tripartite motif containing 46 was initially identified as the oncogene in several human tumors. However, the clinical value and potential functions of tripartite motif containing 46 (TRIM46) in clear cell renal cell carcinoma (ccRCC) remained largely unclear.Methods: The expressing patterns, clinical involvement, and prognostic values of TRIM46 were analyzed using the data obtained from TCGA and GEO databases. A nomogram was constructed to examine the outcome of patients with ccRCC. We estimated the association between TRIM46 with tumor immunity in ccRCC.Results: Tripartite motif containing 46 was highly expressed in ccRCC, and its upregulation revealed an unfavorable prognosis. A nomogram based on TRIM46 expressions and other independent prognostic factors could robustly predict the overall survival of tumor patients. TRIM46 has a strong positive correlation with NUMBL, CACNB1, THBS3, ROBO3, MAP3K12, ANKRD13D, PIF1, PRELID3A, ANKRD13B, and PCNX2. Mechanically, TRIM46 displayed regulatory functions in ccRCC progression via several tumor-associated pathways. Besides, we observed that TRIM46 was distinctly related to tumor immunity in ccRCC.Conclusions: Our findings provide a novel tumor promotive role regarding TRIM46 function in the malignant progression of ccRCC.

Serum exosomal miR‐210 as a potential biomarker for clear cell renal cell carcinoma

2018 ◽  
Vol 120 (2) ◽  
pp. 1492-1502 ◽  
Author(s):  
Xuegang Wang ◽  
Tao Wang ◽  
Chenxi Chen ◽  
Zhun Wu ◽  
Peide Bai ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Potential Biomarker

Emerging role of secreted miR-210-3p as potential biomarker for clear cell Renal Cell Carcinoma metastasis

2020 ◽  
Vol 27 (2) ◽  
pp. 181-188 ◽  
Author(s):  
Vincenzo Petrozza ◽  
Manuela Costantini ◽  
Claudia Tito ◽  
Laura Maria Giammusso ◽  
Veronica Sorrentino ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Potential Biomarker ◽  
Renal Cell Carcinoma Metastasis ◽  
Carcinoma Metastasis

scholarly journals Identification of HIPK3 as a potential biomarker and an inhibitor of clear cell renal cell carcinoma

Aging ◽  
2021 ◽  
Author(s):  
Wen Xiao ◽  
Tao Wang ◽  
Yuzhong Ye ◽  
Xuegang Wang ◽  
Bin Chen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Potential Biomarker

MicroRNA as novel blood-based biomarkers in clear cell renal cell carcinoma.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 375-375 ◽  
Author(s):  
A. Ari Hakimi ◽  
Anders Jacobsen ◽  
Nina Mikkilineni ◽  
Brandon Fiegoli ◽  
Sara Blass ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mirna Expression ◽  
Renal Cell ◽  
Clear Cell ◽  
Expression Patterns ◽  
Integrative Approach ◽  
Cell Renal Cell Carcinoma ◽  
Potential Biomarker ◽  
Plasma Mirna

375 Background: MicroRNAs (miRNA) are short, non-coding RNAs involved in post-transcriptional gene regulation. Several reports have assessed their role as blood based biomarkers given their tissue and cancer-specific expression. Using an integrative approach we sequenced the miRNA transcriptome of the plasma of several clear cell renal cell carcinoma (ccRCC) patients both before and after surgery as well as several controls. Methods: We performed next generation miRNA sequencing (miRNAseq) on eight pairs (pre- and post-operative plasma samples) and four non-cancer controls to identify potential biomarker candidates. We further integrated our data with the miRNAseq tumor data from the Cancer Genome Atlas (TCGA) study to determine whether plasma miRNA levels are representative of tumor miRNA expression in ccRCC. Results: Overall, 930 unique miRNAs were detected, including 272 at greater than or equal to 10 read counts. There was a global shift of miRNA expression toward the non-cancer controls in the postoperative samples compared to preoperative. We further identified several stably expressed miRNAs across all samples and controls including miR-16, miR-191, and miR-103. We also identified several potential biomarker candidates by looking at differential expression both in terms of preoperative and postoperative status, as well as tumor vs. control including miR-378 and miR-660. Intriguingly, the plasma miRNA expression patterns showed no relationship to the tumor expression patterns using the TCGA samples. Conclusions: Plasma miRNA expression patterns are consistently altered in ccRCC and, following surgery, globally revert to the non-cancerous levels of the controls. Several biomarker candidates have been identified and a panel is undergoing validation in larger cohorts. Plasma miRNA levels do not appear to reflect tumor levels in ccRCC.

Sign in / Sign up

Export Citation Format

Share Document